Abstract:Glioblastoma (GBM), the most common primary brain malignancy in adults, is notoriously difficult to treat due to several factors: tendency to be radiation resistant, the presence of the blood brain barrier (BBB) which limits drug delivery and immune-privileged status which hampers effective immune responses. Traditionally, high-dose irradiation (8 Gy) is known to effectively enhance anti-tumor immune responses, but its application is limited by the risk of severe brain damage. Currently, conventional dose segmentation (2 Gy) is the standard radiotherapy method, which does not fully exploit the potential of high-dose irradiation for immune activation. The hypothesis of our study posits that instead of directly applying high doses of radiation, which is risky, a strategy could be developed to harness the immune-stimulating benefits of high-dose irradiation indirectly. This involves using nanoparticles to enhance antigen presentation and immune responses in a safer manner. Angiopep-2 (A2) was proved a satisfactory BBB and brain targeting and Dbait is a small molecule that hijack DNA double strand break damage (DSB) repair proteins to make cancer cells more sensitive to radiation. In view of that, the following two nanoparticles were designed to combine immunity of GBM, radiation resistance and BBB innovatively. One is cationic liposome nanoparticle interacting with Dbait (A2-CL/Dbait NPs) for radiosensitization effect; the other is PLGA-PEG-Mal nanoparticle conjugated with OX40 antibody (A2-PLGA-PEG-Mal/anti-OX40 NPs) for tumor-derived protein antigens capture and optimistic immunoregulatory effect of anti-OX40 (which is known to enhance the activation and proliferation T cells). Both types of nanoparticles showed favorable targeting and low toxicity in experimental models. Specifically, the combination of A2-CL/Dbait NPs and A2-PLGA-PEG-Mal/anti-OX40 NPs led to a significant extension in the survival time and a significant tumor shrinkage of mice with GBM. The study demonstrates that combining these innovative nanoparticles with conventional radiotherapy can effectively address key challenges in GBM treatment. It represents a significant step toward more effective and safer therapeutic options for GBM patients.

Multifunctional targeted liposomal drug delivery for efficient glioblastoma treatment.

Interpreting the Therapeutic Efficiency of Multifunctional Hybrid Nanostructure Against Glioblastoma

Low-Intensity Focused Ultrasound Technique in Glioblastoma Multiforme Treatment.

Design of Y-shaped targeting material for liposome-based multifunctional glioblastoma-targeted drug delivery

Targeted Delivery of Liposomal Temozolomide Enhanced Anti-Glioblastoma Efficacy through Ultrasound-Mediated Blood–Brain Barrier Opening

Stable Peptides Mediated Glioma Targeting Drug Delivery

Peptide-22 and Cyclic Rgd Functionalized Liposomes for Glioma Targeting Drug Delivery Overcoming Bbb and Bbtb

A multifunctional targeted nano-delivery system with radiosensitization and immune activation in glioblastoma

Cell-permeable NF-κB Inhibitor-Conjugated Liposomes for Treatment of Glioma.

Multifunctional Targeting Daunorubicin Plus Quinacrine Liposomes, Modified by Wheat Germ Agglutinin and Tamoxifen, for Treating Brain Glioma and Glioma Stem Cells

Targeted Delivery of Chemo-Sonodynamic Therapy via Brain Targeting, Glutathione-Consumable Polymeric Nanoparticles for Effective Brain Cancer Treatment

Tumor cells and neovasculature dual targeting delivery for glioblastoma treatment

Glioma and Microenvironment Dual Targeted Nanocarrier for Improved Antiglioblastoma Efficacy

Efficient Delivery of Lomitapide Using Hybrid Membrane‐Coated Tetrahedral DNA Nanostructures for Glioblastoma Therapy

Delivering Sirna and Chemotherapeutic Molecules Across BBB and BTB for Intracranial Glioblastoma Therapy

Brain-targeting redox-sensitive micelles for codelivery of TMZ and β-lapachone for glioblastoma therapy

A dual-targeting liposome conjugated with transferrin and arginine-glycine-aspartic acid peptide for glioma-targeting therapy

Glucose and Triphenylphosphonium Co-Modified Redox-Sensitive Liposomes to Synergistically Treat Glioma with Doxorubicin and Lonidamine

A Targeted and Responsive Nanoprodrug Delivery System for Synergistic Glioma Chemotherapy

Development of a Hybrid Nanocarrier-Recognizing Tumor Vasculature and Penetrating the BBB for Glioblastoma Multi-Targeting Therapy.

Multiple targeted doxorubicin-lonidamine liposomes modified with p-hydroxybenzoic acid and triphenylphosphonium to synergistically treat glioma